Skip to main content

Table 3 Comparison of regional citrate anticoagulation versus anticoagulation-free MARS

From: A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System

  Citrate No anticoagulation P
Primary endpoint    
   Completed sessions 14/14 9/13 0.04
Secondary endpoints    
   Clotting score dialyzer (n)    0.009
Clean, white 2 2  
White, limited fibrin deposits, head of dialyzer 7 3  
White, fibrin deposits head and body dialyzer 5 5  
Completely clotted, rinse back successful 0 1  
Completely clotted, rinse back unsuccessful 0 2  
   Platelets (x 103/mm3)    
Start of treatment 112 (58 - 146) 92 (67 - 169) 0.6
End of treatment 85 (67 - 162) 89 (60 - 117) 0.7
Reduction of platelets (P intra-group) 12 (P 0.08) 28 (P 0.0005) 0.03
   aPTT (s)    
Start of treatment 44.1 (40.5 - 57.2) 57.8 (40.7 - 75.4) 0.5
End of treatment 48.0 (41.3 - 61.5) 52.5 (40.0 - 65.7) 0.6
   PT (s)    
Start of treatment 14.2 (13.8 - 16.0) 17.2 (14.6 - 22.0) 0.1
End of treatment 14.5 (14.0 - 16.2) 16.1 (13.8 - 18.3) 0.4
   TAT complex (μg/L)    
End of treatment 9.9 (7.7 - 91.7) 25.7 (19.5 - 40.5) 0.3
Increase during treatment 6.1 (5.1 - 50.1) 25.1 (16.8 - 40.5) 0.09
   Treatment efficacy, all sessions    
Urea reduction ratio 0.51 (0.14) 0.40 (0.14) 0.06
Creatinine reduction ratio 0.40 (0.13) 0.31 (0.17) 0.10
Bilirubin (total) reduction ratio 0.25 (0.09) 0.15 (0.10) 0.02
Bile acids reduction ratio 0.47 (0.20) 0.42 (0.16) 0.34
   Treatment efficacy, completed sessions    
Urea reduction ratio 0.51 (0.14) 0.46 (0.12) 0.4
Creatinine reduction ratio 0.40 (0.13) 0.40 (0.14) 0.9
Bilirubin (total) reduction ratio 0.25 (0.09) 0.18 (0.09) 0.1
Bile acids reduction ratio 0.47 (0.20) 0.46 (0.21) 0.9
  1. aPTT (S), activated partial thromboplastin time (S); MARS, Molecular Adsorbents Recirculation System; PT, prothrombin time (S); TAT complex, thrombin antithrombin complex.